Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Integrated MRI and [11C]‐PBR28 PET Imaging in ALS

Ann Neurol; ePub 2018 May 8; Alshikho, et al

Glial activation measured by in vivo [11C]‐PBR28 positron emission tomography (PET) is increased in pathologically relevant regions in people with amyotrophic lateral sclerosis (ALS) and correlates with clinical measures, according to a recent study. 85 participants—including 53 ALS, 11 primary lateral sclerosis (PLS), and 21 healthy controls—underwent integrated [11C]‐PBR28 PET‐MR brain imaging. Patients were clinically assessed using the upper motor neuron burden (UMNB), and the revised ALS functional rating scale (ALSFRS‐R). [11C]‐PBR28 uptake was quantified as standardized uptake value ratio (SUVR), and compared between groups. Cortical thickness and fractional anisotropy were compared between groups and correlated with SUVR and the clinical data. Researchers found:

  • Whole brain voxel‐wise, surface‐based, and region of interest analyses revealed increased [11C]‐PBR28 uptake in the precentral and paracentral gyri in ALS, and in the sub‐cortical white matter for the same regions in PLS, compared to controls.
  • The increase in [11C]‐PBR28 uptake co‐localized and correlated with cortical thinning, reduced fractional anisotropy, increased mean diffusivity, and correlated with higher UMNB score.
  • No significant changes were detected in [11C]‐PBR28 uptake over 6 months despite clinical progression.
Citation:

Alshikho MJ, Zürcher NR, Loggia ML, et al. Integrated MRI and [11C]‐PBR28 PET imaging in amyotrophic lateral sclerosis. [Published online ahead of print May 8, 2018]. Ann Neurol. doi:10.1002/ana.25251.

This Week's Must Reads

Recurrent Stroke Risk Higher for Blacks than Whites, Neurology; ePub 2018 Oct 3; Albright, Huang, et al

Sleep Duration/Stroke Link Differs by Race and Sex, Neurology; ePub 2018 Oct 3; Petrov, Howard, et al

Intracerebral Hemorrhage Survivors’ Outcomes Studied, J Stroke Cerebrovasc Dis; ePub 2018 Sep 28; Griauzde, et al

Probable OSA Common in Refractory Epilepsy, Epilepsia; ePub 2018 Sep 24; McCarter, et al

FDA Approves Tiglutik for Treatment of ALS, ITF Pharma news release; 2018 Sep 6

Must Reads in Neuromuscular Disorders

FDA Approves Tiglutik for Treatment of ALS, ITF Pharma news release; 2018 Sep 6

FDA Approves Xeomin for Excessive Drooling, Merz North America news release; 2018 Jul 3

Integrated MRI and [11C]‐PBR28 PET Imaging in ALS, Ann Neurol; ePub 2018 May 8; Alshikho, et al

FDA Approves Hizentra for CIDP Treatment, CSL Behring news release; 2018 Mar 16

FDA Approves Soliris for Generalized MG, Alexion news release; 2017 Oct 23